This is NDP-2.1. It results from testimony that was given by MEDEC. It seems to me to be a housekeeping thing that's fairly straightforward. What they were saying is that some of these therapeutic products are very big, such as hospital equipment. In terms of withdrawing them from the market, it couldn't necessarily physically happen—or it would be very difficult—that you could move something to a central quarantine. We've proposed this amendment by just saying, after line 28 on page 3 the following, “quarantine the product; or”, so that it actually allows something to be quarantined where it is without it having to be moved.
It is based on something that MEDEC raised with us and it seemed to be a logical thing to do to prevent unnecessary damage or storage costs for some of the larger equipment.